登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LILRB4】

LILRB4信息

英文名称:Leukocyte immunoglobulin-like receptor subfamily B member 4
中文名称:免疫抑制受体LILRB4
靶点别称:CD85k Antigen,Leukocyte immunoglobulin-like receptor 5,Immunoglobulin-like transcript 3,CD85k,CD85 antigen-like family member K,LIR-5,Monocyte inhibitory receptor HM18,ILT-3,Leucocyte Ig-Like Receptor B4,ILT3,LIR5,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4,HM18,Leukocyte Immunoglobulin Like Receptor B4
上市药物数量:0
临床药物数量:6
最高研发阶段:临床二期

LILRB4产品列表

ACRO质量管理体系
 
评论(0)
 

LILRB4分子别名

LILRB4,ILT3,LIR5,CD85K,HM18

LILRB4分子背景

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定